Lipoprotein

1. PCSK9 inhibitors decrease lipoprotein in humans (-15.3%).

   Humans3 months

   Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study · Atherosclerosis · 23 Sep 2026

PCSK9 inhibitors →

1. Antisense oligonucleotides decrease lipoprotein in humans (65% to >95%).

   Review

   Lipoprotein(a) in the statin era: from risk marker to therapeutic target · Frontiers in pharmacology · 16 Sep 2026

Antisense oligonucleotides →

1. Lipoprotein raises the risk of atherothrombosis.

   Review

   The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps · Current atherosclerosis reports · 30 Sep 2026

Atherothrombosis →

1. Lipoprotein raises the risk of atherosclerosis.

   Review

   The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps · Current atherosclerosis reports · 30 Sep 2026

Atherosclerosis →

1. Lipoprotein raises the risk of coronary heart disease in humans.

   Review

   The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps · Current atherosclerosis reports · 30 Sep 2026

Coronary heart disease →

1. Lipoprotein raises the risk of calcific aortic valve stenosis in humans.

   Review

   Lipoprotein(a) in the statin era: from risk marker to therapeutic target · Frontiers in pharmacology · 16 Sep 2026

Calcific aortic valve stenosis →

1. Lipoprotein raises the risk of residual cardiovascular risk in humans.

   Reviewdespite effective LDL-cholesterol lowering in the statin era

   Lipoprotein(a) in the statin era: from risk marker to therapeutic target · Frontiers in pharmacology · 16 Sep 2026

1. Lipoprotein is associated with QRISK3 in humans (1.4%, 1.4%, and 1.8%).

   Humansn = 14,848

   Lipoprotein(a) levels and estimated QRISK3 cardiovascular risk in the Randox Health 2025 cohort: a cross-sectional analysis of 14,848 individuals · Frontiers in cardiovascular medicine · 16 Sep 2026

QRISK3 →

1. C-reactive protein is associated with lipoprotein in humans (APR = 1.015).

   “diabetes status significantly modified the association between CRP and elevated Lp(a) interaction (APR = 1.015)”

   Humansn = 2,083

   Associations of Elevated Lipoprotein(a) with C-Reactive Protein and Type 2 Diabetes in a Multiethnic Population · Biomedicines · 5 Sep 2026

C-reactive protein →

1. Type 2 diabetes is associated with lipoprotein in humans (APR = 1.166).

   “individuals with T2D had a higher prevalence of elevated Lp(a) (APR = 1.166)”

   Humansn = 2,083

   Associations of Elevated Lipoprotein(a) with C-Reactive Protein and Type 2 Diabetes in a Multiethnic Population · Biomedicines · 5 Sep 2026

Type 2 diabetes →

1. Lipoprotein is associated with myocardial infarction in humans.

   Reviewindependent of LDL-C

   Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed? · American journal of cardiovascular disease · 15 Aug 2026

Myocardial infarction →